HAMS-AB
/ Rise Therap
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
December 10, 2025
Microbial production of short-chain fatty acids attenuates long-term neurologic impairment after traumatic brain injury.
(PubMed, J Neuroinflammation)
- "Diet-facilitated microbial production of acetate and butyrate attenuates behavioral deficits of LTNI after TBI and produces enduring benefits at the single-cell level on the neuro-inflammatory and neuro-progenitor responses. This therapeutic approach could have a broader potential to prevent neurodegenerative disease."
Journal • Alzheimer's Disease • CNS Disorders • Inflammation • Vascular Neurology
May 30, 2025
Study on How Nerve Signalling is Affected by a High-Fibre Supplement in Untreated Hypertensive Individuals.
(ANZCTR)
- P=N/A | N=29 | Not yet recruiting | Sponsor: Professor Francine Marques - Monash University
New trial • Cardiovascular • Hypertension
October 29, 2024
Safety and effects of acetylated and butyrylated high-amylose maize starch on youths recently diagnosed with type 1 diabetes: A pilot study.
(PubMed, Diabetes Obes Metab)
- No abstract available
Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
September 19, 2024
Effect of Prebiotics on the Gut Microbiome Profile and Beta Cell Function
(clinicaltrials.gov)
- P1 | N=12 | Completed | Sponsor: Indiana University | Phase classification: P3 ➔ P1
Phase classification • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • IL2RA • ISG20
January 12, 2024
HAMSAB diet ameliorates dysfunctional signaling in pancreatic islets in autoimmune diabetes.
(PubMed, iScience)
- "Finally, SCFA increased insulin levels in human β-like cells and improved transplantation outcome in NOD/SCID mice. Our findings support the use of metabolite-based diet as attractive approach to improve glucose control in T1D."
Journal • Diabetes • Immunology • Metabolic Disorders • Obesity • Transplantation • Type 1 Diabetes Mellitus
September 28, 2023
HAMS-AB-01B: HAMS-AB in Newly Diagnosed Patients With Type 1 Diabetes
(clinicaltrials.gov)
- P1 | N=39 | Not yet recruiting | Sponsor: Rise Therapeutics LLC
New P1 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
1 to 6
Of
6
Go to page
1